IsomAb appoints Dr Philip Brainin as Chief Executive Officer [Yahoo! Finance]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Yahoo! Finance
Strong preclinical data demonstrates ISM-001's novel disease-modifying mechanism to re-establish healthy angiogenesis Chronic Stable Angina is a major undertreated condition affecting 9 million US patients Dr. Brainin brings extensive translational and investment experience in cardiology Preparing for Series A fundraise with new Chair Dr Anker Lundemose NOTTINGHAM, England March 18, 2026 /PRNewswire/ -- IsomAb Ltd, a UK-based biotechnology company, today announced the appointment of Dr Philip Brainin as Chief Executive Officer (CEO) and member of the Board of Directors. IsomAb is developing transformative isoform-specific antibody therapeutics for atherosclerotic disease. Dr Brainin is tasked with taking lead candidate ISM-001 for chronic stable angina (CSA) into clinical development. ISM-001's strong preclinical data showing complete restoration of blood flow in severe ischemic disease models supports the company's stated goal of delivering a disease-modifying treatment for
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- Astellas Pharma (ALPMY) was upgraded by Jefferies Financial Group Inc. from "hold" to "strong-buy".MarketBeat
- JAMP Pharma Group Expands Oncology Portfolio with PrJAMP Enzalutamide [Yahoo! Finance]Yahoo! Finance
- BioNTech's Founding Duo Will Leave to Start New mRNA Firm [Yahoo! Finance Canada]Yahoo! Finance Canada
- BioNTech's Founding Duo Will Leave to Start New mRNA Firm [Yahoo! Finance]Yahoo! Finance
- Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? [Yahoo! Finance]Yahoo! Finance